Resources

Stay informed with the latest news, research, and information about memory health and Alzheimer's care.

Medical researcher reviewing brain scan data

Clinical Update

New TGA-Approved Alzheimer's Therapies

The Therapeutic Goods Administration (TGA) has approved two new treatments for people with Mild Cognitive Impairment (MCI) or early Alzheimer's disease: Donanemab (brand name Kisunla) and Lecanemab (brand name Leqembi). These represent a significant advance in Alzheimer's care and are now available at The Memory Centre for eligible patients.

Patient eligibility criteria:

  • Evidence of a "rapid forgetting" pattern of memory impairment
  • Diagnosis of mild cognitive impairment or mild dementia due to Alzheimer's disease
  • Minimal impairment in daily functioning
  • MMSE score between 20 and 28
  • Confirmed amyloid pathology on brain imaging